Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 403

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 403
---
 in a currency other than their functional currency, the
Group’s transactions outside the UK to the US and Europe drive foreign exchange movements where suppliers invoice in currency other
than sterling. The Group does retain some cash balances in US Dollars from its US Dollar denominated equity raises to reduce the foreign
exchange exposure on US$ denominated suppliers related to its NASDAQ listing and US based clinical trial. All other assets and/or consumables
that are purchased in foreign currencies, such currency is purchased immediately upon invoice. These transactions are not hedged because
the cost of doing so is disproportionate to the risk.

Foreign currency sensitivity analysis

The most significant
currencies in which the Group transacts, other than Pounds Sterling, are the US Dollar and the Euro. The Group also trades in other currencies
in small amounts as necessary.

The following table
details the Group’s sensitivity to a 10% change in year-end exchange rates, which the Group feels is the maximum likely change in
rate based upon recent currency movements, in the key foreign currency exchange rates against Pounds Sterling:

| Schedule of foreign currency exchange rates 
 Year ended 31 December 2023                 |     | US Dollar £’000 |     | Euro £’000 |     | Other £’000 |
|:--------------------------------------------|:----|----------------:|:----|-----------:|:----|:------------|
| Loss before tax                             |     |             373 |     |          2 |     | –           |
| Total equity                                |     |             373 |     |          2 |     | –           |

| Year ended 31 December 2022 |     | US Dollar £’000 |     | Euro £’000 |   |     | Other £’000 |
|:----------------------------|:----|----------------:|:----|:-----------|:--|:----|:------------|
| Loss before tax             |     |              25 |     | (1         | ) |     | –           |
| Total equity                |     |              25 |     | (1         | ) |     | –           |

| Year ended 31 December 2021 |     | US Dollar £’000 |     | Euro £’000 |     | Other £’000 |
|:----------------------------|:----|:----------------|:----|-----------:|:----|:------------|
| Loss before tax             |     | –               |     |          2 |     | –           |
| Total